title: Hepatitis A in French hemophiliacs.
abstract: The prevalence of serum antibodies to hepatitis A virus (HAV) in 793 hemophilia A (HA) and 89 hemophilia B (HB) patients coming from 10 French Hemophilia Centers and treated since 1986-1987 with solvent/detergent (SD)-treated products is reported. The results indicated seropositivity to HAV of 29.9% in HA and 40.4% in HB patients. There was no difference among the patients according to severity of the disease, HIV serology or administration of factor VIII during the last 12 months. Seropositivity increased with age from 5.2% in HA children to 42.4% in adults (in HB the respective prevalences in the same groups were 7.7% and 56.1%). When compared to normal controls (n = 585), the prevalence of HAV seropositivity was not excessive in HA patients (n = 206). 19/20 children exclusively treated with a very-high-purity SD-factor VIII concentrate (Centre régional de transfusion sanguine, Lille) remained HAV seronegative. Six cases of HAV contamination were reported in patients with severe HA, probably reflecting the level of HAV endemy in the normal population in France. No special risk of HAV transmission linked to the SD products used in France since 1986 had thus been identified.
authors.affiliation: Centres Régionaux de Traitement de l'Hémophilie de Lille, France.
authors.forename: J
authors.initials: J
authors.lastname: Goudemand
authors.forename: A
authors.initials: A
authors.lastname: Parquet
authors.forename: R
authors.initials: R
authors.lastname: d'Oiron
authors.forename: N
authors.initials: N
authors.lastname: Stieltjes
authors.forename: C
authors.initials: C
authors.lastname: Guérois
authors.forename: J
authors.initials: J
authors.lastname: Fonlupt
authors.forename: M
authors.initials: M
authors.lastname: Alcalay
authors.forename: C
authors.initials: C
authors.lastname: Négrier
authors.forename: J P
authors.initials: JP
authors.lastname: Cazenave
authors.forename: M E
authors.initials: ME
authors.lastname: Briquel
mesh_terms: D000293:Adolescent; D000328:Adult; D016913:Blood Component Transfusion / Q000009:adverse effects*; D002648:Child; D005169:Factor VIII / Q000009:adverse effects; D005602:France / Q000453:epidemiology; D006467:Hemophilia A / Q000628:therapy*; D006506:Hepatitis A / Q000453:epidemiology* / Q000635:transmission; D006801:Humans; D008297:Male; D015995:Prevalence
chemical_list: D005169:Factor VIII